The clinical research on autonomous bone marrow stem cells to treat decompensated cirrhosis

Objective To evaluate the the clinical efficacy and safety of trans-artery intrahepatic autonomous bone marrow stem cell treatment in patients with decompensated liver cirrhosis. Methods 50 hospitalized patients with decompensated liver cirrhosis in our department from November 2009 to February 2011 were divided into 2 matched groups.There were 25 patients in the treatment group, 25 patients in the control group.Bone marrow 200 ml were extracted from patients in treatment group, and bone marrow stem cells were purified in vitro and made into 10 ml cell suspension, then injected into the liver through the hepatic artery.The laboratory parameters, clinical signs and symptoms of adverse reactions were observed respectively at the 4, 8, 16 weeks after treatment compared with the control group.Results After treatment, all patients' symptoms were improved.After 8 weeks treatment, the symptom of ascites in 16 cases was decreased (80%) , the appetite in 18 cases was improved (90%) , the symptom of fatigue in 19 cases was improved (95%) , the symptom of abdominal distension in 18 cases was alleviated (90%) .After 8 weeks treatment in control group, the symptom of ascites in 10 patients was decreased (50%) , the appetite in 12 cases was having been improved (60%) , the symptom of fatigue in 10 cases was improved (50%) , the symptom of abdominal distension in 8 cases was alleviated (40%) .The laboratory parameters in patients in treatment group were changed after 4 weeks stem cell treatment, to 8 weeks a number of indicators showing significant change.After 8 weeks and 16 weeks treatment, the alanine aminotransferase (ALT) 、Total bilirubin (TBil) 、 albumin (Alb) , 、total cholesterol (CHO) , prothrombin time (PT) show significant difference compared with before treatment.At 8 weeks and 16 weeks in treatment group and control group, the indicators of ALT、Alb、TBil、PT、CHO, were statistically significant.CTP score changes before and after treatment, starting from the 4th week, patients with CTP score dropped significantly.To 8 weeks and 16 weeks, the changes were most obvious, compared with before treatment there was significant difference.Treatment group and control group also had significant differences.MELD score from 4 weeks after treatment began to decline, after treatment 8th week and when 16 week, compared with before treatment there was significant difference, compared with the control group are also significant differences.25 cases did not occur in patients with serious complications, and no adverse reactions appeared recently.Conclusion Autonomous bone marrow stem cell to treat patients with liver failure treatment is effective and clinical, security good, as a means in the clinical treatment of patients with advanced liver cirrhosis.